• 00:00 1.
    index 1
  • 27:01 2.
    HBV
  • 30:05 3.
    Slide 2
  • 32:06 4.
    Slide 3
  • 33:10 5.
    Slide 2
  • 33:14 6.
    Slide 3
  • 33:19 7.
    Slide 2
  • 33:21 8.
    Slide 3
  • 35:10 9.
    Chronic carrier- HBs Ag+ ≧ 6m
  • 36:27 10.
    Infancy’s fulminant hepatitis in Taiwan
  • 37:14 11.
    HBV vaccine
  • 41:00 12.
    保護力: 母 HBeAg + → 子 ① HBIG + 1st HBV vaccine => 85-95% 保護力 ② 1st HBV vaccine => 70-80% 保護力 母 HBeAg -, anti-HBe +carrier rate: 10%vaccine+: carrier rate: 4%; be wary of 6-9% become fulminant hepatitisVaccine+, HBIG+
  • 42:11 13.
    Slide 8
  • 42:49 14.
    Slide 9
  • 43:30 15.
    Pretreatment evaluation
  • 45:50 16.
    Testing for coinfection1. HCV – Test for HCV in all children with HBV Coinfection with HCV increases the risk for progressive liver disease informs decisions about antiviral treatment, because of the risk of HBV reactivation during treatment for HCV Hepa
  • 46:40 17.
    Antiviral treatment of chronic HBV in children
  • 47:55 18.
    Slide 13
  • 51:14 19.
    Antiviral treatment of chronic HBV in children
  • 52:21 20.
    ** after HBV comment.pptx
  • 索引
  • 筆記
  • 討論
  • 全螢幕
20240117_GI conference
長度: 59:42, 瀏覽: 49, 最近修訂: 2024-01-26 我要推薦
    評語
    統計結果不開放
    請登入後才可以評分
    • 00:00 1.
      index 1
    • 27:01 2.
      HBV
    • 30:05 3.
      Slide 2
    • 32:06 4.
      Slide 3
    • 33:10 5.
      Slide 2
    • 33:14 6.
      Slide 3
    • 33:19 7.
      Slide 2
    • 33:21 8.
      Slide 3
    • 35:10 9.
      Chronic carrier- HBs Ag+ ≧ 6m
    • 36:27 10.
      Infancy’s fulminant hepatitis in Taiwan
    • 37:14 11.
      HBV vaccine
    • 41:00 12.
      保護力: 母 HBeAg + → 子 ① HBIG + 1st HBV vaccine => 85-95% 保護力 ② 1st HBV vaccine => 70-80% 保護力 母 HBeAg -, anti-HBe +carrier rate: 10%vaccine+: carrier rate: 4%; be wary of 6-9% become fulminant hepatitisVaccine+, HBIG+
    • 42:11 13.
      Slide 8
    • 42:49 14.
      Slide 9
    • 43:30 15.
      Pretreatment evaluation
    • 45:50 16.
      Testing for coinfection1. HCV – Test for HCV in all children with HBV Coinfection with HCV increases the risk for progressive liver disease informs decisions about antiviral treatment, because of the risk of HBV reactivation during treatment for HCV Hepa
    • 46:40 17.
      Antiviral treatment of chronic HBV in children
    • 47:55 18.
      Slide 13
    • 51:14 19.
      Antiviral treatment of chronic HBV in children
    • 52:21 20.
      ** after HBV comment.pptx
    臺中榮民總醫院
    407219臺中市西屯區臺灣大道四段1650號
    總機:(04)2359-2525
    全人智慧 醫療典範
    愛心品質 創新當責
    本站內容為臺中榮民總醫院所有,未經允許請勿任意轉載ヽ複製或做商業用途
    臺中榮民總醫院護理部 著作權所有